Drug intelligence / Profile preview

Pangramin Plus

Development stage
Phase 4
Lead developer
ALK Abelló
Modality
Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration
Subcutaneous
01

Overview

Pangramin Plus is a brand of allergen extract vaccine used for subcutaneous allergen immunotherapy (SCIT). It contains intact, unmodified allergen extracts derived from sources such as grass pollen (5-grass mix) and house dust mite (*Dermatophagoides pteronyssinus*), among others. The product is designed to induce immune tolerance in patients with allergic conditions, particularly local allergic rhinitis (LAR) and other IgE-mediated allergies. Its mechanism of action involves repeated exposure to increasing doses of the relevant allergens, leading to immunological changes such as increased production of specific IgG4 antibodies and reduced clinical reactivity upon natural or provoked exposure. Clinical studies have shown that Pangramin Plus is effective in reducing symptoms and medication use in patients with LAR, with a good safety profile comparable to conventional schedules but allowing for shorter initiation periods[1][3][4][6][10].

Brand names
Pangramin Plus
02

Targets

sIgG4 (Allergen-specific immunoglobulin G4)A. annua-specific IgE (Artemisia annua-specific immunoglobulin E)

Beyond the preview

Go deeper on Pangramin Plus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pangramin Plus.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call